Synthesis and in vitro Antiproliferative Evaluation and Molecular Docking Studies of Novel Chalcone‐Phosphonates Derivatives as Anticancer Agents

Shweta Mishra,Ekta Verma,Biplab Debnath,Amit Chawla,Prasanna Shama Khandige,Bhagawati Saxena,Nityananda Sahoo,Pardip Jana
DOI: https://doi.org/10.1002/slct.202400689
2024-06-20
ChemistrySelect
Abstract:A series of 18 new chalcone‐phosphonates hybrid derivatives were synthesized and screened for anti‐proliferative activity against MCF7, HeLa, and A549 cell lines. Compound 3 l, 3 m, and 3p exhibited potent anti‐proliferative activity. Further, molecular docking, in silico pharmacokinetic (ADME) and toxicity studies were performed to assessed the results. Based on the wide range of pharmacological aspects related to organophosphates, a new type of chalcone‐phosphonate containing derivatives were synthesized by the reaction of dialkyl phosphite and substituted chalcones using anhydrous Mg(ClO4)2 at 80 °C under solvent‐free conditions. The resulting compounds were evaluated for anti‐proliferative activity in vitro against a panel of three human cancer cell lines: MCF7, HeLa, and A549 cell lines. Compound 3 l, 3 m, and 3 p exhibited anti‐proliferative activity against MCF7 and HeLa, with IC50 values of 1.12 μM, 1.63 μM, 1.09 μM and 1.29 μM, 1.44 μM, 2.40 μM respectively. The molecular docking study showed that the synthesized derivatives have good binding ability in the active site of the Vaccinia H1‐related (VHR) phosphatase (PDB: 3F81), PI3‐ kinase (PDB: 3R7Q), androgen receptor (PDB: 3V49) and VEGFR2 kinase (PDB: 3VHE). Finally, in silico pharmacokinetic (ADME) and toxicity studies revealed that compounds have the drug‐like feature for the favourable bioavailability. In conclusion, this work confirmed the potency of chalcone‐phosphonates derivatives for the further optimization of potential anti‐ proliferative agents.
chemistry, multidisciplinary
What problem does this paper attempt to address?